Bradford [3], with bovine serum albumin as a calibrator. Ghosts were diluted to protein contents of 0.5, 1, 1.5, 2, and 2.5 g/L. The samples with protein contents of 0.5 g/L (low activity), 1.5 g/L (medium activity), and 2.5 g/L (high activity) were divided into aliquots and stored at Ϫ80°C until the measurements.
Comparison of Antinuclear Antibody Testing Methods by ROC Analysis with Reference to Disease Diagnosis, Richard A.
Gniewek, 1* Carla Sandbulte, 2 and Philip C. Fox 3 ( 1 Bio-Rad Labs., 4000 Alfred Nobel Dr., Hercules, CA 94547; 2 Arthritis Center of Nebraska, Lincoln, NE 68506; 3 Natl. Inst. of Dental Res., NIH, Bethesda, MD 20892-1190; * address for correspondence: fax 510-741-5824, email rich_gniewek@bio-rad.com) Assessing the concentration of antinuclear antibodies (ANA) in a patient's serum is commonly done by the ANA-immunofluorescence assay (ANA-IFA) [1] [2] [3] [4] [5] [6] , a very tedious and subjective procedure. By contrast, ANA enzyme immunoassays (ANA-EIA) are easy to perform, and the results are not subjective. Although the performance of ANA-EIA was judged to be less than satisfactory [7] , five different ANA-EIA kits were recently proven to be comparable with ANA-IFA [8] . Similarly, in a recent study involving one of us [9] , a comparison of ROC curves for ANA-IFA and ANA-EIA showed equivalent performance. In this study we generated ROC curves with disease diagnosis as the gold standard and compared them with the ROC curves from the earlier study [10] . We also tested 98 serum samples from patients with primary Sjö gren syndrome (SS).
The patients' serum samples entered into this study from the Arthritis Center of Nebraska (ACN) were part of the routine medical care when ANA-IFA was ordered. A total of 283 serum samples were collected from April 4, [11] . All of these samples were part of the daily laboratory routine, and none of the samples processed by the laboratory during this period was excluded. The 98 serum samples from patients diagnosed with primary SS had been stored frozen at the National Institute of Dental Research of the National Institutes of Health until needed for testing by ANA-EIA. Diagnosis of primary SS was made according to established criteria [12] . All information regarding ACN samples, which included ANA-IFA results, age, sex, diagnosis, and medications, was withheld until ANA-EIA results had been sent back to ACN. All information regarding primary SS samples was withheld until ANA-EIA results had been generated and sent back to NIH.
Samples from the ACN were tested by ANA-IFA (Kallestad Quantafluor; Sanofi Diagnostics Pasteur) according to the manufacturer's instructions. Samples from NIH were tested by ANA-IFA (ANA-HEp-2; ImmunoConcepts) according to the manufacturer's instructions. Samples were then stored frozen (Ϫ20°C) and shipped to Bio-Rad Labs., where they were tested by ANA-EIA with the automated analyzer Radias (Bio-Rad). The Radias instrument was programmed by the manufacturer to interpret ANA-EIA results of Ͻ0.9 as negative, 0.9 to 1.1 as indeterminate, and Ͼ1.1 as positive. The ANA-EIA plates for the Radias are coated with a HEp-2 cell extract containing ANA antigens, which include double-stranded DNA, SS antigen A (SS-A/Ro), SS antigen B (SS-B/La), Sm, ribonucleoprotein (RNP), Jo-1, and Scl-70.
Diagnostic sensitivity, specificity, positive predictive value, negative predictive value, and agreement were calculated with standard formulas [2] . These values were calculated after defining those diagnoses for which ANA is commonly used as a part of connective tissue disease (CTD) diagnosis as disease-positive. Hence, systemic lupus erythematosus, discoid lupus erythematosus, scleroderma/CREST (calcinosis, Raynaud phenomenon, esophageal motility abnormalities, sclerodactyly, and telangiectasia), Raynaud syndrome, SS, MCTD, overlap CTD syndromes, polymyositis, and dermatomyositis were considered disease-positive [11] and all other diagnoses were considered disease-negative. The exact McNemar statistic [10] was used to compare sensitivities and specificities. The 95% confidence intervals (CI) and ROC curves were constructed, and the areas under the curves were compared [13] .
Approximately 14% (39 of 283) of the ACN samples entered into this study were from patients diagnosed with a CTD. The most common diagnosis was systemic lupus erythematosus (n ϭ 16), followed by Raynaud syndrome (n ϭ 6), SS (n ϭ 6), scleroderma/CREST (n ϭ 5), MCTD (n ϭ 3), discoid lupus erythematosus (n ϭ 2), dermatomyositis/polymyositis (n ϭ 2), and an undefined CTD (n ϭ 9). Some of these patients were diagnosed with more than one CTD.
The area under the ROC curve for ANA-IFA ( Fig. 1A ) was 0.804 (CI 0.758 -0.850) and did not differ significantly (P Ͼ0.05) from the area under the ROC curve for ANA-EIA, which was 0.817 (CI 0.772-0.862). The ROC curve for the ANA-IFA from this study did not differ significantly (P Ͼ0.05) from the ROC curves for the ANA-IFA in the previous study (Fig. 1B) .
With a reference range of Ͻ1:80 for the ANA-IFA, the sensitivity, specificity, positive predictive value, and negative predictive value were 64.1%, 80.7%, 34.7%, and 93.4%, respectively. With a reference range of Ͻ1.2 for the ANA-EIA, the sensitivity, specificity, positive predictive value, and negative predictive value were 71.8%, 76.2%, 32.6%, and 94.4%, respectively. Comparison of the sensitivity and specificity between the ANA-IFA with a reference range of Ͻ1:80 and the ANA-EIA with a reference range of Ͻ1.2 showed no significant difference (P Ͼ0.05).
When we tested the 98 serum samples from patients diagnosed with primary SS with a reference range for ANA-IFA of Ͻ1:80 and a reference range of Ͻ0.9 for ANA-EIA, 6 samples were commonly called negative and Fig. 1 . ROC curves for ANA-EIA ACN and ANA-IFA ACN (from this study with samples from the ACN) (A) and ROC curves for ANA-IFA ACN, ANA-IFA USCF1 (for the overall period), and ANA-IFA UCSF2 (for the common period) (ROC curves from Gniewek et al. [9] reproduced with permission) (B). 86 samples were commonly called positive. With these reference ranges, the difference between the sensitivity for ANA-IFA (88.8%) and ANA-EIA (92.9%) was not significant (P Ͼ0.05). The agreement between the two methods was 93.9%. Some bias may have been introduced into this study because the ANA-IFA results were used by the physicians to establish diagnoses whereas the ANA-EIA results were not made available to the physicians. Although it may be reasonable to assume that this bias favored the ANA-IFA, it would be difficult to determine the extent of this bias because no definitive test for CTD exists.
Although information on patterns is lost with the ANA-EIA method, this may be a minor disadvantage. The ANA-IFA fluorescent patterns have been associated with certain clinical states [1] [2] [3] [4] [5] [6] , but no matter how convincing such associations may seem, they are difficult to confirm when unselected patients are used [14] . The earlier study [9] reported that only 3 of 8 patients with anticentromere antibody had a diagnosis of CREST syndrome, and only 1 of 19 patients with nucleolar antibody had a diagnosis of scleroderma. In this study, 2 of 4 patients with anticentromere antibody had a diagnosis of CREST, and none of the 4 patients with nucleolar antibody had a diagnosis of scleroderma. Although the association of certain patterns with certain clinical states has been reported, the incidence of these patterns in non-CTD clinical states has not been investigated thoroughly.
We conclude that the ANA-EIA method is equivalent to the ANA-IFA in screening for ANA in serum from patients with CTD. Differences in performance between the ANA-EIA and ANA-IFA may be insignificant when the appropriate cutoffs are selected. The appropriate cutoff may depend on many factors including the cost of false negatives and false positives as well as the prevalence of CTD. The ANA-EIA has the advantage of being easy to use, and the results are objective.
IMx Tacrolimus II vs IMx Tacrolimus Microparticle Enzyme Immunoassay Evaluated in Renal and Hepatic
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In 1992, an automated whole-blood microparticle enzyme immunoassay was developed (Abbott Labs.) for the measurement of tacrolimus concentrations (TAC I) on the IMx analyzer [1] . This method involves the antitacrolimus monoclonal antibody developed by Fujisawa Pharmaceutical, the company producing the immunosuppressant tacrolimus [2] . The assay requires 100 L of whole blood, and 24 samples can be analyzed in ϳ40 min after a rapid organic extraction (200 L of precipitation reagent: ZnSO 4 solution in methanol and ethylene glycol). The capture reagent consists of latex microparticles to which tacrolimus antibodies are attached, the enzyme is tacrolimusconjugated alkaline phosphatase, and the substrate is 4-methylumbelliferyl phosphate. This method yields CVs of ϳ10% (11.8% and 9.6% at concentrations of 15 and 25 g/L, respectively) [1] , but is limited by the detection limit of 5 g/L. Because in current clinical practice a nonnegligible percentage of transplant patients display low tacrolimus concentrations (Ͻ6 g/L), the immunoassay has recently been modified. A new assay, IMx tacrolimus II (TAC II), with a lower detection limit, has been developed, requiring 150 L of whole blood and 150 L of precipitation reagent. Whereas the TAC I has a dynamic range of quantification from 5 to 60 g/L, the TAC II assay has a range from 1 to 30 g/L, better corresponding to the therapeutic range of tacrolimus (5-15 g/L) [3] . Because this new assay will replace the TAC I, we have evaluated and compared the two assays in terms of their analytical performances, and their correlation in clinical
